Klinische Pharmakologie von Disulfiram - eine aktuelle Übersicht[1]

Zusammenfassung

Der gegenwärtig zu beobachtende Anstieg an Verschreibungen von Disulfiram setzt ärztliche Kenntnisse bezüglich Pharmakodynamik, -kinetik, Nebenwirkung und Wechselwirkung der Substanz voraus. Wir geben eine Übersicht über die Pharmakologie und unerwünschte Nebenwirkungen der Substanz Disulfiram. Beispielhaft wird ein Fall vorgestellt, bei welchem ein akutes neurologisches Defizit zunächst als Nebenwirkung von Disulfiram verkannt wurde. Diskutiert werden mögliche Perspektiven von Disulfiram in der Suchtmedizin.

Abstract

Recently, we have been observing an increase in prescription of Disulfiram requiring medical knowledge concerning the overall effects, side effects and drug interactions of this substance. In the following report, we give an overview about the pharmacology and the side effects of Disulfiram. As an example we demonstrate a case, in which an acute neurological deficit was misjudged as a side effect of Disulfiram. Furthermore, the potential of Disulfiram as a promising treatment in addiction medicine will be discussed.

Schlüsselwörter

Disulfiram - Alkohol - Nebenwirkungen - Wechselwirkungen - Arzneimittel-Interaktionen

Key words

Disulfiram - alcohol - side effects - adverse drug reactions - drug interactions

1 Interessenkonflikt. Es besteht kein Interessenkonflikt. Die Autoren versichern, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Literatur

• 1 De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence.  Alcohol Alcohol. 2004;  39 528-531
• 2 De Sousa A, De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence.  Alcohol Alcohol. 2005;  40 545-548
• 3 Krampe H, Stawicki S, Wagner T. et al . Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.  Alcohol Clin Exp Res. 2006;  30 86-95
• 4 Chick J, Gough K, Falkowski W. et al . Disulfiram treatment of alcoholism.  Br J Psychiatry. 1992;  161 84-89
• 5 Datenlieferungen nach § 300 SGB V, Wissenschaftliches Institut der AOK WldO. 2007
• 6 Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.  Acta Psychiatr Scand Suppl. 1992;  369 15-26
• 7 Brewer C. How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice.  Br J Psychiatry. 1984;  144 200-202
• 8 Madan A, Parkinson A, Faiman M D. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation.  Alcohol Clin Exp Res. 1998;  22 1212-1219
• 9 Elenbaas R M. Drug therapy reviews: management of the disulfiram-alcohol reaction.  Am J Hosp Pharm. 1977;  34 827-831
• 10 Amadoe M, Gazdar A. Sudden death during disulfiram-alcohol reaction.  Q J Stud Alcohol. 1967;  28 649-654
• 11 Guild J, Epstein N B. Psychosis during the treatment of alcoholism with tetraethylthiuram disulfide.  Q J Stud Alcohol. 1951;  12 360-366
• 12 Jacobsen E. Deaths of alcoholic patients treated with disulfiram (tetraethylthiuram disulfide) in Denmark.  Q J Stud Alcohol. 1952;  13 16-26
• 13 Fuller R K, Branchey L, Brightwell D R. et al . Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.  JAMA. 1986;  256 1449-1455
• 14 Fuller R K, Gordis E. Does disulfiram have a role in alcoholism treatment today?.  Addiction. 2004;  99 21-24
• 15 Green A L. The inhibition of dopamine-B-oxidase by chelating agents.  Biochem biophys Acta. 1964;  81 394-397
• 16 Mays D C, Ortiz-Bermudez P, Lam J P, Tong I H, Fauq A H, Lipsky J J. Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram.  Biochem Pharmacol. 1998;  55 1099-1103
• 17 Karamanakos P N, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism.  Pharmacol Toxicol. 2001;  88 106-110
• 18 Musacchio J M, Goldstein M, Anagnoste B, Poch G, Kopin I J. Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo.  J Pharmacol Exp Ther. 1966;  152 56-61
• 19 Paradisi R, Grossi G, Pintore A. et al . Evidence for a pathological reduction in brain dopamine metabolism in idiopathic hyperprolactinemia.  Acta Endocrinol (Copenh). 1991;  125 246-252
• 20 Rosen G F, Lobo R A. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1987;  65 891-895
• 21 Amit Z, Levitan D E, Lindros K O. Suppression of ethanol intake following administration of dopamine-beta-hydroxylase inhibitors in rats.  Arch Int Pharmacodyn Ther. 1976;  223 114-119
• 22 Kohnke M D, Zabetian C P, Anderson G M. et al . A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function.  Biol Psychiatry. 2002;  52 1151-1158
• 23 Kohnke M D, Kolb W, Kohnke A M, Lutz U, Schick S, Batra A. DBH*444G/A polymorphism of the dopamine-beta-hydroxylase gene is associated with alcoholism but not with severe alcohol withdrawal symptoms.  J Neural Transm. 2006;  113 869-876
• 24 Ewing J A, Rouse B A, Mueller R A, Silver D. Can dopamine beta-hydroxylase levels predict adverse reactions to disulfiram?.  Alcohol Clin Exp Res. 1978;  2 93-94
• 25 Heath R G, Nesselhof Jr  W, Bishop M P, Byers L W. Behavioral and metabolic changes associated with administration of tetraethylthiuram disulfide (antabuse).  Dis Nerv Syst. 1965;  26 99-105
• 26 Major L F, Lerner P, Ballenger J C, Brown G L, Goodwin F K, Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis.  Biol Psychiatry. 1979;  14 337-344
• 27 Cubells J F, Kranzler H R, Cance-Katz E. et al . A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia.  Mol Psychiatry. 2000;  5 56-63
• 28 Poikolainen K. The disulfiram-ethanol reaction (DER) experience.  Addiction. 2004;  99 6-28
• 29 Ehrenreich H, Krampe H. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects.  Addiction. 2004;  99 26-27
• 30 Martensen-Larsen O. Psychotic phenomena provoked by tetraethylthiuram disulfide.  Q J Stud Alcohol. 1951;  12 206-216
• 31 Christensen J K, Ronsted P, Vaag U H. Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study.  Acta Psychiatr Scand. 1984;  69 265-273
• 32 Fuller R K, Branchey L, Brightwell D R. et al . Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.  JAMA. 1986;  256 1449-1455
• 33 Poulsen H E. Disulfiram therapy - adverse drug reactions and interactions. Loft S, Andersen JR, Andersen M (eds).  Acta Psychiatr Scand. 1992;  86 59-66
• 34 Branchey L, Davis W, Lee K K, Fuller R K. Psychiatric complications of disulfiram treatment.  Am J Psychiatry. 1987;  144 1310-1312
• 35 Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury.  J Hepatol. 2006;  44 791-797
• 36 Frisoni G B, Di Monda V. Disulfiram neuropathy: a review (1971 - 1988) and report of a case.  Alcohol Alcohol. 1989;  24 429-437
• 37 Berglund M. A better widget? Three lessons for improving addiction treatment from a meta-analytical study.  Addiction. 2005;  100 742-750
• 38 Mann K, Lehert P, Morgan M Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.  Alcohol Clin Exp Res. 2004;  28 (1) 51-63
• 39 Kiefer F, Jahn H, Tarnaske T. et al . Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.  Arch Gen Psychiatry. 2003;  60 92-99
• 40 Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.  Alcohol Clin Exp Res. 1998;  22 573-579
• 41 Landabaso M A, Iraurgi I, Sanz J. et al . Naltrexone in the treatment of alcoholism. Two-year follow up results.  Eur J Psychiatry. 1999;  13 97-105
• 42 Petrakis I L, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.  Biol Psychiatry. 2005;  57 1128-1137
• 43 Petrakis I L, Poling J, Levinson C. et al . Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder.  Biol Psychiatry. 2006;  60 777-783
• 44 Weinshenker D, Schroeder J P. There and Back Again: A Tale of Norepinephrine and Drug Addiction.  Neuropsychopharmacology. 2007;  32 1433-1451
• 45 Finney J W, Monahan S C. The cost-effectiveness of treatment for alcoholism: a second approximation.  J Stud Alcohol. 1996;  57 229-243
• 46 Miller W R, Wilbourne P L. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.  Addiction. 2002;  97 265-277
• 47 Fuller R K, Branchey L, Brightwell D R. et al . Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.  JAMA. 1986;  256 1449-1455
• 48 Kellam A M, Wesolkowski J M. Disulfiram implantation for alcoholism.  Lancet. 1968;  1 925-926
• 49 Wilson A, Davidson W J, Blanchard R, White J. Disulfiram implantation. A placebo-controlled trial with two-year follow-up.  J Stud Alcohol. 1978;  39 809-819
• 50 Hughes J C, Cook C C. The efficacy of disulfiram: a review of outcome studies.  Addiction. 1997;  92 381-395
• 51 Suh J J, Pettinati H M, Kampman K M, O"Brien C P. The status of disulfiram: a half of a century later.  J Clin Psychopharmacol. 2006;  26 290-302
• 52 Matching Alcoholism Treatments to Client Heterogeneity . Project MATCH posttreatment drinking outcomes.  J Stud Alcohol. 1997;  58 7-29
• 53 Moos R H, Finney J W, Ouimette P C, Suchinsky R T. A comparative evaluation of substance abuse treatment: I. Treatment orientation, amount of care, and 1-year outcomes.  Alcohol Clin Exp Res. 1999;  23 529-536
• 54 Brewer C. Long-term, high-dose disulfiram in the treatment of alcohol abuse.  Br J Psychiatry. 1993;  163 687-689
• 55 Carroll K M, Fenton L R, Ball S A. et al . Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.  Arch Gen Psychiatry. 2004;  61 264-272
• 56 Fritze J. Psychopharmaka-Verordnungen - Ergebnisse und Kommentare zum Arzneiverordnungsreport 2005.  Psychoneuro. 2006;  32 44-53
• 57 Kiefer F, Jahn H, Holzbach R, Briken P, Stracke R, Wiedemann K. Die NALCAM-Studie: Wirksamkeit, Verträglichkeit, Outcome.  Sucht. 2003;  49 (6) 342-351

1 Interessenkonflikt. Es besteht kein Interessenkonflikt. Die Autoren versichern, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.